| I-06 Raouf EL Cheikh A New Protocol for the Administration of Etoposide–Cisplatin in Metastatic Small Cell Lung Cancer Wednesday 10:20-11:40 |
| I-09 Eric Fernandez Modelling and translating head and neck radiation therapy on all three levels: in vitro, in vivo and clinical Wednesday 10:20-11:40 |
| I-16 María García-Cremades A comparison of different model-based approaches to scale preclinical to clinical tumour growth inhibition in gemcitabine-treated pancreatic cancer Wednesday 10:20-11:40 |
| I-20 Ekaterina Gibiansky Population Pharmacokinetic of Obinutuzumab (GA101) in Patients with Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma (FL), Other Indolent Non-Hodgkin’s Lymphoma (iNHL) Subtypes, Diffuse Large B-cell Lymphoma (DLBCL), and Mantle Cell Lymphoma (MCL) Wednesday 10:20-11:40 |
| I-28 Sebastiaan Goulooze Monte-Carlo simulations of sunitinib therapeutic drug monitoring in patients with gastrointestinal stromal tumours. Wednesday 10:20-11:40 |
| I-30 Joachim Grevel Exposure-response analysis for efficacy and safety of sorafenib in patients with differentiated thyroid carcinoma (DTC) Wednesday 10:20-11:40 |
| I-31 Monia Guidi Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients Wednesday 10:20-11:40 |
| I-37 Fangran Hao Pharmacokinetic-pharmacodynamic modeling of the anti-tumor effect of sunitinib combined with dopamine in the human non-small cell lung cancer xenograft Wednesday 10:20-11:40 |
| I-40 Andrea Henrich PK/PD model extension to characterise bone marrow exhaustion in cancer patient making use of a prior paclitaxel PK model Wednesday 10:20-11:40 |
| I-42 Jennifer Hibma Population Pharmacokinetic/Pharmacodynamic Evaluation of the Effect of Inotuzumab Ozogamicin on QT Intervals in ALL and NHL Patients Wednesday 10:20-11:40 |
| I-50 Diane-Charlotte Imbs Modeling and simulation for improving the efficacy of the combination between antiangiogenic and chemotherapy in Non Small Cell Lung Cancer Wednesday 10:20-11:40 |
| I-59 Matts Kågedal Selection of exposure metrics AUC, Cmax or Cmin in exposure response analyses – a simulation study. Wednesday 10:20-11:40 |
| I-63 Lena Klopp-Schulze Tamoxifen and endoxifen pharmacokinetics: Exploration of differences in model performance using simulations Wednesday 10:20-11:40 |
| II-04 Maurice Ahsman Modelling and simulation of oral GnRH Antagonist TAK-385 and testosterone-lowering response in Prostate Cancer Patients to Optimize Trial Design and Dose Selection Wednesday 15:10-16:30 |
| II-05 Sihem Bihorel A plateform PK/PD Model for Antibody Drug Conjugates Induced Myelosuppression Wednesday 15:10-16:30 |
| II-27 Jennifer Bonner Building of virtual geriatric cancer populations for physiologically-based pharmacokinetic modelling and simulation in cancer patients greater than 70 years of age Wednesday 15:10-16:30 |
| II-36 Tim Cardilin Extending the Tumor Static Concentration curve to average doses – a combination therapy example using radiation therapy Wednesday 15:10-16:30 |
| II-40 Pascal Chanu A model to predict progression free survival in patients with previously untreated HER2-positive progressive or recurrent locally advanced or metastatic breast cancer based on tumor growth inhibition metrics Wednesday 15:10-16:30 |
| II-43 Christophe Chassagnole Modelling the Emergence of Resistance to Chemotherapeutics with Virtual Tumour Wednesday 15:10-16:30 |
| II-48 Laurent Claret A model to predict progression-free survival in patients with renal cell carcinoma based on week 8 change in tumor size Wednesday 15:10-16:30 |
| II-55 Damien Cronier PK/PD Modeling of Overall and Progression-Free Survival in Advanced Soft Tissue Sarcoma Patients Treated With Olaratumab in Combination with Doxorubicin. Wednesday 15:10-16:30 |
| II-61 Bernardo de Miguel Lillo Modeling the dynamics of alanine aminotransferase in advanced cancer patients treated with kahalalide F Wednesday 15:10-16:30 |
| II-63 Aurelia de Vries Schultink Pharmacokinetics of MCLA-128 in cynomolgus monkeys and extrapolation to humans to support selection of first-in-human dose Wednesday 15:10-16:30 |
| II-67 Laurence Del Frari Predicting human pharmacokinetics of monoclonal antibodies by allometric translation from preclinical data: a case study Wednesday 15:10-16:30 |
| III-09 Sreenath M Krishnan Population modeling of uni- and three- dimensional and density-based tumor measurements in gastro-intestinal stromal tumor (GIST) patients treated with imatinib Thursday 10:05-11:30 |
| III-21 Litaty Céphanoée Mbatchi Pharmacokinetics modelling of temsirolimus and its active metabolite Thursday 10:05-11:30 |
| III-23 Evgeny Metelkin Development of immune responce template forsystems pharmacology modeling of immunotherapy in oncology Thursday 10:05-11:30 |
| III-44 Zinnia Parra-Guillen Pharmacokinetic analysis of midazolam and caffeine as probe drugs for cytochrome phenotyping in erlotinib treatment Thursday 10:05-11:30 |
| III-47 Belén Pérez Solans Markov model for tumor shrinkage effects of combination therapy in non-metastatic gastric cancer patients Thursday 10:05-11:30 |
| III-56 Philippe Pierrillas From mouse to human: comparison of interspecies translational strategies using integrative semi-mechanistic PK-PD models and PBPK-PD modeling to forecast efficacious clinical dose Thursday 10:05-11:30 |
| IV-05 Emilie Schindler PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients Thursday 14:40-16:00 |
| IV-09 Kevin Smart Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab Thursday 14:40-16:00 |
| IV-16 Oleg Stepanov A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions Thursday 14:40-16:00 |
| IV-24 Rob ter Heine The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients Thursday 14:40-16:00 |
| IV-27 Hoai-Thu Thai Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients Thursday 14:40-16:00 |
| IV-29 Yingying Tian Population pharmacokinetic analysis of everolimus in patients with solid tumors Thursday 14:40-16:00 |
| IV-33 Elena Tosca Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment Thursday 14:40-16:00 |
| IV-34 Mira Tout Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia Thursday 14:40-16:00 |
| IV-55 Siyuan Wang An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer Thursday 14:40-16:00 |
| IV-64 Jan-Georg Wojtyniak A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome Thursday 14:40-16:00 |
| IV-70 Huixin Yu Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours Thursday 14:40-16:00 |
| IV-76 Li Zhu Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma Thursday 14:40-16:00 |
